Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491073 | 0.84 | KDM4E (0.46) | KDM4EMAPK1ALDH1A1MAPTCYP3A4 | |
| SCHEMBL28673707 | 0.83 | APLNR (0.50) | APLNRKDM4EMAPK1ALDH1A1MAPT | |
| SCHEMBL1491059 | 0.81 | NPBWR1 (0.48) | KDM4EALDH1A1MAPTCYP3A4LMNA | |
| SCHEMBL28206624 | 0.80 | KDM4E (0.48) | APLNRKDM4EMAPK1ALDH1A1MAPT | |
| SCHEMBL1491062 | 0.78 | MEN1 (0.49) | KDM4EALDH1A1MAPTLMNATSHR | |
| SCHEMBL1491091 | 0.78 | CHRM2 (0.47) | KDM4EALDH1A1MAPTDHFRLMNA | |
| SCHEMBL18692166 | 0.78 | APLNR (0.48) | APLNRKDM4EMAPK1TP53ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29442137 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1MAPTCYP3A4PKM | |
| Hydrochloric Acid SCHEMBL540053 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1MAPTCYP3A4PKM | |
| SCHEMBL4435852 | 0.75 | KMT2A (0.43) | KDM4EALDH1A1LMNAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | REPARE THERAPEUTICS INC. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-114174292-B | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| CN-114174292-A | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors | 修复治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113454080-A | Compounds, pharmaceutical compositions and methods of making compounds and methods of use thereof | 修复治疗公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190144441-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-16 | — | — | US | disclosed |
| WO-2017196982-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | APLNR 3684/4885KDM4E 3402/4885MAPK1 3377/4885 |
| US-20250179070-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | APLNR 4277/4885KDM4E 3285/4885MAPK1 1229/4885 |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | APLNR 4619/4885KDM4E 2564/4885MAPK1 1196/4885 |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | NIPSNAP3A, ZC3HAV1, SARNP | APLNR 3597/4885KDM4E 4730/4885MAPK1 4002/4885 |
| US-20190144441-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | NIPSNAP3A, ZC3HAV1, SARNP | APLNR 3597/4885KDM4E 4730/4885MAPK1 4002/4885 |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | APLNR 747/4885KDM4E 2955/4885MAPK1 3086/4885 |
| US-12264155-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors | ATR, CHEK2, CHEK1 | APLNR 4277/4885KDM4E 3285/4885MAPK1 1229/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | APLNR 4277/4885KDM4E 3285/4885MAPK1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.